Piotr Wojciechowski

Krakow, MA, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria.

Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria.

Journal: Journal of comparative effectiveness research

Published: August 24, 2026

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Journal: Expert review of hematology

Published: June 19, 2026

Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysis.

Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysis.

Journal: NPJ vaccines

Published: February 27, 2026

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.

Journal: Advances in therapy

Published: February 17, 2026

Can We Trust PAICs in Rare Diseases? Methodological Challenges and Limitations.

Can We Trust PAICs in Rare Diseases? Methodological Challenges and Limitations.

Journal: Journal of market access & health policy

Published: November 24, 2025

Between Rigor and Relevance: Why the EU HTA Guidelines on Indirect Comparisons Miss the Mark.

Between Rigor and Relevance: Why the EU HTA Guidelines on Indirect Comparisons Miss the Mark.

Journal: Journal of market access & health policy

Published: June 02, 2025

Comparative Efficacy of Elinzanetant Versus Other Non-Hormonal Pharmaceutical Therapies for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Network Meta-Analysis.

Comparative Efficacy of Elinzanetant Versus Other Non-Hormonal Pharmaceutical Therapies for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Network Meta-Analysis.

Journal: BJOG : an international journal of obstetrics and gynaecology

Published: May 27, 2025

Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria.

Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria.

Journal: European journal of haematology

Published: December 06, 2024

Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis.

Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis.

Journal: Ophthalmology and therapy

Published: November 28, 2024

Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors.

Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors.

Journal: Advances in therapy

Published: May 28, 2024

Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors.

Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors.

Journal: Advances in therapy

Published: May 28, 2024

Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis.

Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis.

Journal: EClinicalMedicine

Published: September 15, 2023

Showing 1-12 of 23

Last Updated: 09/26/2026